CS MEDICA Offers Shareholders the Opportunity to Transfer Delisted Shares Before 31 December 2025

CS MEDICA has launched a voluntary, cost-free administrative option for holders of its delisted shares to transfer their stock to the company by 31 December 2025 to avoid bank custody fees; the company stresses the transfers are not buybacks or tender offers and no payment or compensation will be made. Transferred shares will be received at a book value of 0 DKK per share, and shareholders are advised to consult tax advisors as they may, depending on jurisdiction, document deductible losses. CS MEDICA says the measure is purely administrative, optional, and part of broader efforts to strengthen operations with the long-term aim of a potential future relisting, though no timeline is provided.

Analysis

CS MEDICA offers shareholders a voluntary, cost-free administrative option to transfer delisted shares to the company through 31 December 2025; transferred shares will be recorded at 0 DKK per share and the company explicitly states the program is not a buyback, tender offer, or incentive. The service is intended to help holders avoid additional custody fees charged by banks, and shareholders are advised to seek tax advice because, depending on jurisdiction, removal from custody may allow documentation of a tax-deductible loss. The transfer is purely administrative and involves no payment or consideration, so it will not affect the company’s cash position or constitute a return of capital.

The initiative formalizes a register cleanup while liquidity remains constrained because the company is delisted, meaning marketability of remaining holdings is impaired pending any relisting. CS MEDICA reiterates it is working to strengthen operations with the long‑term aim of a future relisting but provides no timeline; the company highlights MDR‑approved, CBD‑based products, a capital‑light model, and European production partners as strategic assets. The sentiment signal is moderately negative and market impact is low, consistent with an administrative remedy rather than a near‑term value-creating corporate action; risks include continued illiquidity and uncertain tax outcomes for shareholders.

Key Decisions for Investors

• If custody fees are material and a deductible loss is likely in your jurisdiction, consider transferring shares to CS MEDICA before 31 December 2025 after obtaining tax advice
• Do not expect cash recovery from this program—treatment is administrative at zero value—so reduce exposure if you cannot tolerate illiquidity or lack conviction in a future relisting
• Monitor company disclosures for operational milestones, concrete relisting timelines, or changes to capital structure that would materially alter valuation prospects